MX2016017368A - Metodos y composiciones para la estimulacion del sistema enteroendocrino intestinal para el tratamiento de enfermedades o condiciones relacionadas con el mismo. - Google Patents

Metodos y composiciones para la estimulacion del sistema enteroendocrino intestinal para el tratamiento de enfermedades o condiciones relacionadas con el mismo.

Info

Publication number
MX2016017368A
MX2016017368A MX2016017368A MX2016017368A MX2016017368A MX 2016017368 A MX2016017368 A MX 2016017368A MX 2016017368 A MX2016017368 A MX 2016017368A MX 2016017368 A MX2016017368 A MX 2016017368A MX 2016017368 A MX2016017368 A MX 2016017368A
Authority
MX
Mexico
Prior art keywords
methods
stimulation
compositions
same
treating diseases
Prior art date
Application number
MX2016017368A
Other languages
English (en)
Inventor
Zasloff Michael
Original Assignee
Zasloff Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zasloff Michael filed Critical Zasloff Michael
Publication of MX2016017368A publication Critical patent/MX2016017368A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a métodos para estimular la actividad del sistema nervioso entérico humano y animal; el método comprende administrar oralmente un aminosterol, como escualamina, un aminosterol natural que se encuentra aislado de Squalus acanthias, o derivados del mismo, a un sujeto en necesidad.
MX2016017368A 2014-06-23 2015-06-22 Metodos y composiciones para la estimulacion del sistema enteroendocrino intestinal para el tratamiento de enfermedades o condiciones relacionadas con el mismo. MX2016017368A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015657P 2014-06-23 2014-06-23
US14/329,627 US10040817B2 (en) 2013-10-03 2014-07-11 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
PCT/US2015/036935 WO2015200195A1 (en) 2014-06-23 2015-06-22 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Publications (1)

Publication Number Publication Date
MX2016017368A true MX2016017368A (es) 2017-08-24

Family

ID=54869043

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016017368A MX2016017368A (es) 2014-06-23 2015-06-22 Metodos y composiciones para la estimulacion del sistema enteroendocrino intestinal para el tratamiento de enfermedades o condiciones relacionadas con el mismo.
MX2021005489A MX2021005489A (es) 2014-06-23 2016-12-20 Metodos y composiciones para la estimulacion del sistema enteroendocrino intestinal para el tratamiento de enfermedades o condiciones relacionadas con el mismo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021005489A MX2021005489A (es) 2014-06-23 2016-12-20 Metodos y composiciones para la estimulacion del sistema enteroendocrino intestinal para el tratamiento de enfermedades o condiciones relacionadas con el mismo.

Country Status (18)

Country Link
US (10) US10040817B2 (es)
EP (1) EP3157531B1 (es)
JP (2) JP6692300B2 (es)
CN (2) CN106535902B (es)
BR (1) BR112016029917A2 (es)
CA (1) CA2951720C (es)
CY (1) CY1124554T1 (es)
DK (1) DK3157531T3 (es)
ES (1) ES2878077T3 (es)
HR (1) HRP20211005T1 (es)
HU (1) HUE054828T2 (es)
LT (1) LT3157531T (es)
MX (2) MX2016017368A (es)
PL (1) PL3157531T3 (es)
PT (1) PT3157531T (es)
RS (1) RS62064B1 (es)
SI (1) SI3157531T1 (es)
WO (1) WO2015200195A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
WO2018222665A1 (en) * 2017-05-31 2018-12-06 Enterin Laboratories, Inc. Methods and compositions for preventing or treating inflammatory diseases
WO2019050903A1 (en) * 2017-09-08 2019-03-14 Enterin Laboratories, Inc. METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS
EP3704132A4 (en) * 2017-10-30 2021-07-28 Enterin, Inc. NEW SOLID FORMS OF SQUALAMINE AND PROCESSES FOR PRODUCING THEM
MX2020010086A (es) * 2018-03-27 2021-03-25 Enterin Inc Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas.
AU2019285065A1 (en) * 2018-06-13 2021-01-07 Enterin, Inc. Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
US20210260078A1 (en) * 2018-08-03 2021-08-26 Philadelphia Low dosage intranasal aminosterol dosage forms and methods of using the same
US20210315907A1 (en) * 2018-08-03 2021-10-14 Enterin, Inc, Compositions and methods for treating brain-gut disorders
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. COMPOSITIONS AND METHODS FOR TREATING GUT-BRAIN AXIS DISORDERS
WO2021025988A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
US5352682A (en) 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
ATE169930T1 (de) 1993-03-10 1998-09-15 Magainin Pharma Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
WO1996008270A2 (en) 1994-09-13 1996-03-21 Magainin Pharmaceuticals Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5834453A (en) 1995-05-30 1998-11-10 Lehigh University Methods for the manufacture and use of antimicrobial sterol conjugates
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5994336A (en) 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
CA2223910C (en) * 1995-06-07 2008-09-16 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5874597A (en) 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
WO1997040835A1 (en) 1996-04-26 1997-11-06 Magainin Pharmaceuticals Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
JP2002515035A (ja) 1996-05-17 2002-05-21 ジェネーラ・コーポレーション アミノステロール化合物の治療学的使用
WO1998019682A1 (en) 1996-11-01 1998-05-14 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and uses therefor
EP1105407B1 (en) 1998-08-12 2007-10-10 Genaera Corporation Aminosterol compounds and uses thereof
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
AU2002230398A1 (en) 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
WO2002044324A2 (en) * 2000-10-06 2002-06-06 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
EP2942082B1 (en) * 2002-01-28 2019-03-06 Kyowa Hakko Kogyo Co., Ltd A2a receptor antogonists for use in the treatment of movement disorders
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
CA2606077C (en) 2005-04-25 2013-07-09 Genaera Corporation Polymorphic and amorphous salt forms of squalamine dilactate
CA2922021C (en) * 2007-09-06 2018-01-09 Ohr Pharmaceutical, Inc. A method for treating diabetes
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
US8623416B2 (en) 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
KR102057812B1 (ko) 2012-04-20 2019-12-19 오에이치알 파마서티컬, 인코포레이티드 Ptp1b 연관 질병의 치료용 아미노스테로이드
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2014100679A1 (en) 2012-12-20 2014-06-26 Mount Desert Island Biological Laboratory Stimulation and enhancement of regeneration of tissues
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Also Published As

Publication number Publication date
HRP20211005T1 (hr) 2021-09-17
US11440936B2 (en) 2022-09-13
LT3157531T (lt) 2021-07-12
JP2017519775A (ja) 2017-07-20
CN106535902B (zh) 2021-05-25
JP6692300B2 (ja) 2020-05-13
CA2951720C (en) 2023-09-26
US10975116B2 (en) 2021-04-13
DK3157531T3 (da) 2021-07-05
US20180002370A1 (en) 2018-01-04
EP3157531A4 (en) 2018-05-16
US10633413B2 (en) 2020-04-28
US10208079B2 (en) 2019-02-19
US20220220148A1 (en) 2022-07-14
WO2015200195A1 (en) 2015-12-30
US20180327445A1 (en) 2018-11-15
CA2951720A1 (en) 2015-12-30
US20170327530A1 (en) 2017-11-16
PL3157531T3 (pl) 2021-11-15
BR112016029917A2 (pt) 2017-08-22
SI3157531T1 (sl) 2021-09-30
US10208080B2 (en) 2019-02-19
US20190185513A1 (en) 2019-06-20
US20170326156A1 (en) 2017-11-16
RS62064B1 (sr) 2021-07-30
US10040817B2 (en) 2018-08-07
MX2021005489A (es) 2021-06-18
US20180319837A1 (en) 2018-11-08
EP3157531A1 (en) 2017-04-26
US20150368290A1 (en) 2015-12-24
JP2020097587A (ja) 2020-06-25
PT3157531T (pt) 2021-07-01
US10196420B2 (en) 2019-02-05
CY1124554T1 (el) 2022-07-22
US20190194243A1 (en) 2019-06-27
HUE054828T2 (hu) 2021-10-28
ES2878077T3 (es) 2021-11-18
EP3157531B1 (en) 2021-03-31
CN106535902A (zh) 2017-03-22
JP7010979B2 (ja) 2022-02-10
CN113559108A (zh) 2021-10-29
US20190194244A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
MX2021005489A (es) Metodos y composiciones para la estimulacion del sistema enteroendocrino intestinal para el tratamiento de enfermedades o condiciones relacionadas con el mismo.
HK1246712A1 (zh) 神經刺激治療疾病及病症
EP3389725A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP3506926A4 (en) NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
EP3452166A4 (en) INTRANASAL STIMULATION FOR THE TREATMENT OF DISEASES OF MEIBOM'S GLANDS AND BLEPHARITIS
EP3364970A4 (en) METHODS OF TREATING NEURODEGENERATIVE DISEASES USING GENE THERAPY TO DELAY THE TRIGGERING AND EVOLUTION OF THE DISEASE WHILE CONFERRING COGNITIVE PROTECTION
EP3119913A4 (en) Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
IL290980A (en) Rna for the treatment of autoimmune diseases
MX2018014114A (es) Derivados del sobetiroma.
IL264070A (en) Methods and preparations for the treatment of disorders and diseases involving rdh12
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
EP3484526A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASE
IL259710A (en) Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases
MA40406A (fr) Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin
EP3341012A4 (en) METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
IL278906A (en) Compositions and methods for treating diseases or disorders related to steroid hormones
IL272604A (en) Preparations for the treatment of intestinal infections
HUE058268T2 (hu) Ursodeoxikolsav-származékok policisztás betegségek kezelésére
EP3402531A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP3500591A4 (en) COMPOSITIONS AND METHODS FOR TREATING BONE-ASSOCIATED DISEASES
IL280952A (en) Methods and drug compounds for the treatment of ophthalmic diseases
EP3720552A4 (en) NEURAL INHIBITION METHODS FOR TREATMENT OF INTESTINAL DISEASES AND DISORDERS